JNJ-1661010

JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics[1][2].

Product Specifications

CAS Number

[681136-29-8]

Product Name Alternative

Takeda-25

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FAAH

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/jnj-1661010.html

Purity

99.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC=C1)N(CC2)CCN2C3=NC(C4=CC=CC=C4)=NS3

Molecular Formula

C19H19N5OS

Molecular Weight

365.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Keith JM, et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2008 Sep 1;18 (17) :4838-43.|[2]Karbarz MJ, et al. Biochemical and biological properties of 4- (3-phenyl-[1,2,4] thiadiazol-5-yl) -piperazine-1-carboxylicacid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg. 2009 Jan;108 (1) :316-29.